LUMIGAN 0.1/MG EYE DROPS 3ML

Indications

Approved Uses

Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Off-Label Uses

Eyelash hypotrichosis is treated with bimatoprost 0.03% topical solution (Latisse) rather than Lumigan eye drops; other proposed uses (e.g., eyebrow hypotrichosis/alopecia) are not established for this product and are not guideline-supported.

Dosage & Administration

Dosing by Condition

Open-angle glaucoma or ocular hypertension (elevated IOP): 1 drop in the affected eye(s) once daily in the evening; do not exceed once daily.

Initial Dose

One drop (approximately 1.5 mcg bimatoprost per drop) instilled into the affected eye(s) once daily in the evening

Maintenance Dose

One drop in affected eye(s) once daily in the evening (same as initial dose - no titration required)

Maximum Dose

One drop in the affected eye(s) once daily (typically in the evening); do not administer more than once daily.

Children's Dosage

Safety and efficacy in pediatric patients have not been established.

Dose Adjustment Notes

No routine dose adjustment is required for age, renal impairment, or hepatic impairment; do not administer more than once daily (more frequent dosing may reduce IOP-lowering effect). Use with caution in patients at risk for macular edema (e.g., aphakia/pseudophakia with torn posterior capsule).

How to Take

Instill 1 drop in the affected eye(s) once daily in the evening. Wash hands; avoid touching the dropper tip. Pull down lower eyelid and instill into the conjunctival sac; close eye gently and perform nasolacrimal occlusion for 1-2 minutes. Remove contact lenses before use and reinsert after 15 minutes. If using other ophthalmic products, separate by at least 5 minutes.

Side Effects

Common Side Effects

Conjunctival hyperemia (eye redness), ocular pruritus, eye irritation/burning/stinging, foreign body sensation, dry eye, eyelash growth, periocular skin hyperpigmentation, and increased iris pigmentation (may be permanent).

Side Effect Frequency

Very common (>10%): conjunctival hyperemia; eyelash growth. Common (1-10%): eye pruritus, ocular irritation/burning/stinging, dry eye, foreign body sensation, eyelid/skin hyperpigmentation. Uncommon (<1%): macular edema, uveitis/iritis.

Safety & Warnings

Warnings & Precautions

Warn about potential permanent iris pigmentation; eyelash changes and periocular skin darkening; prostaglandin-associated periorbitopathy (deepening of eyelid sulcus); use caution with active intraocular inflammation and in patients at risk for macular edema (e.g., aphakia/pseudophakia with posterior capsule tear); benzalkonium chloride may be absorbed by soft contact lenses-remove lenses and wait ~15 minutes before reinsertion; unilateral use may cause cosmetic asymmetry.

Age Restriction

Safety and efficacy in pediatric patients (<16 years) have not been established; use is not recommended unless directed by a specialist.

Drug Interactions

Drug Interactions

Avoid/limit concomitant use with other prostaglandin analogs (e.g., latanoprost, travoprost) because more frequent/prostaglandin combination therapy may reduce IOP-lowering efficacy or cause paradoxical IOP increase; clinically significant systemic interactions are unlikely at ophthalmic doses.

Interaction Severity

MODERATE: Concomitant use with other prostaglandin/prostamide analog ophthalmic agents (e.g., latanoprost, travoprost, tafluprost) is generally not recommended due to potential paradoxical IOP increase or reduced/unpredictable effect. MINOR/clinical consideration: multiple benzalkonium chloride-preserved drops may worsen ocular surface irritation/toxicity.

Special Populations

Pregnancy

Consult Doctor

Children

Safety and efficacy in pediatric patients have not been established.

Elderly

Standard adult dosing; no dose adjustment required

Kidney Impairment

No dosage adjustment is recommended in renal impairment; use caution in severe impairment due to limited data.

Liver Impairment

No dosage adjustment is recommended in hepatic impairment; use caution in severe impairment due to limited data.

Storage & Patient Advice

Storage Conditions

Store below 25°C; do not store in refrigerator. Discard 4 weeks after first opening.

Stopping the Medicine

Consult an ophthalmologist before stopping; intraocular pressure may rise back toward baseline after discontinuation.

Patient Counseling

Use 1 drop once daily in the evening; do not use more often. Remove contact lenses and reinsert after 15 minutes. Avoid contaminating the dropper tip; consider nasolacrimal occlusion for 1-2 minutes. Expect possible eye redness/irritation; eyelashes may grow/darken and periocular skin may darken; iris color may darken permanently and may be asymmetric if used in one eye. Seek care for eye pain, sudden vision changes, or signs of inflammation. Store below 25°C (per SFDA).

Monitoring Requirements

Monitor intraocular pressure and optic nerve/visual fields per glaucoma care; periodically assess for iris/periocular pigmentation changes and eyelash changes, and monitor for signs/symptoms of uveitis or macular edema in at-risk patients.

Pharmacology

Mechanism of Action

Bimatoprost is a prostamide (prostaglandin analog) that lowers intraocular pressure by increasing aqueous humor outflow via both uveoscleral and trabecular (conventional) pathways.

Duration of Effect

Approximately 24 hours (supports once-daily dosing).

Half-Life

Approximately 45 minutes (systemic/plasma terminal half-life after ophthalmic administration).

Bioavailability

Systemic absorption after ophthalmic use is low; peak plasma concentrations occur rapidly (about 10 minutes) and are very low (on the order of ~0.08 ng/mL).

Metabolism

Metabolized primarily via oxidation, N-deethylation, and glucuronidation (hepatic metabolism); bimatoprost acid is the major circulating active-related species.

Product Information

Available Dosage Forms

Ophthalmic solution (eye drops).

Composition per Dose

Each 1 mL of solution contains 0.1 mg bimatoprost; excipients include benzalkonium chloride 0.02 mg/mL as preservative, sodium chloride, sodium phosphate dibasic, citric acid monohydrate, hydrochloric acid/sodium hydroxide (pH adjustment), purified water

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Target Organ

Eye

Preservative Free

No

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.